C. D. Balincourt

Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors

L. Collette, S. Fosså, C. Sternberg, 2005 .

Phase II study of XR 5000 ( DACA ) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme

D. Lacombe, M. Bent, M. Campone, 2002 .

Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC).

D. Lacombe, J. Machiels, Yan Liu, 2017, European journal of cancer.

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

L. Collette, J. Witjes, C. Sternberg, 2006, European journal of cancer.

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

L. Collette, C. Sternberg, J. Schornagel, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative study of intravesical instillation of epirubicin, BCG, or BCG + INH in intermediate and high risk pTa-pT1 papillary carcinoma of the urinary bladder. First results of EORTC 30911

R. Sylvester, R. Velthoven, M. Brausi, 1997 .

Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study.

M. J. van den Bent, D. Lacombe, E. Raymond, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Le tacrolimus : succès et MAT !

C. D. Balincourt, A. Milesi-Lecat, K. Soulier-Guérin, 2023, La Revue de Médecine Interne.

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.

G. Peters, A. Ravaud, D. Lacombe, 2005, European journal of cancer.

Potential prognostic value in human breast cancer of cytosolic Nme1 protein detection using an original hen specific antibody.

C. Toulas, G. Favre, J. Mihura, 1996, British Journal of Cancer.

Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract.

L. Collette, C. Sternberg, P. D. De Mulder, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.